Search

Supplemental Digital Content is available in the text, Four risk scores for stratifying patients with chest pain presenting to emergency departments (EDs) (namely Thrombolysis in myocardial infarction [TIMI], Global registry for acute coronary events [GRACE], Banach and HEART) have been developed in Western settings but have never been compared and validated in Chinese patients. We aimed to find out to the number of MACE within 7 days, 30 days, and 6 months after initial ED presentation, and also to compare the prognostic performance of these scores in Chinese patients with suspected cardiac chest pain (CCP) to predict 7-day, 30-day, and 6-month major adverse cardiac events (MACE). A prospective 2-center observational cohort study of consecutive patients presenting with chest pain to the EDs of 2 university hospitals in Guangdong and Hong Kong from 17 March 2012 to 14 August 2013 was conducted. Patients aged ≥18 years with suspected CCP but without ST-segment elevation myocardial infarction (STEMI) were recruited. Of 833 enrolled patients (mean age 65.1 years, SD14.5; 55.6% males), 121 (14.5%) experienced MACE within 6 months (4.8% with safety outcomes and 10.3% with effectiveness outcomes). The HEART score had the largest area under the receiver operating characteristic (ROC) curve for predicting MACE at 7-day, 30-day, and 6-month follow-up [area under curve (AUC) = 0.731, 0.726, and 0.747, respectively. The HEART score also had the largest AUC for predicting effectiveness outcome (AUC = 0.715, 0.704, and 0.721, respectively). However, there was no significant difference in AUC between HEART and TIMI scores. Banach had the largest AUC for predicting safety outcome (AUC = 0.856, 0.837, and 0.850, respectively). The HEART score performed better than the GRACE and Banach scores to predict total MACE and effectiveness outcome in Chinese patients with suspected CCP, whereas the Banach score best predicted safety outcomes.

To investigate whether rhegmatogenous retinal detachment (RRD) alters intraocular soluble syndecan-1 levels.In all, 39 samples of subretinal fluid (SRF) and 10 samples of vitreous fluid from RRD patients were collected. Using ELISA, soluble syndecan-1 levels were detected, and potential correlations between syndecan-1 levels with clinical parameters were analyzed.Soluble syndecan-1 in the vitreous fluid (2.577+/-0.578 ng/ml) and in the SRF (1.499+/-0.184 ng/ml) from eyes with RRD enhanced significantly compared to that of the controls (0.224+/-0.095 ng/ml) (p0.0001 and p=0.006). An increase in the syndecan-1 concentrations in SRF samples correlated with a longer duration of retinal detachment (r=0.716, p0.0001) and a younger age (r= -0.341, p=0.017).RRD was found to be associated with a significant increase of soluble syndecan-1 in the vitreous fluid and SRF. In SRF, an enhanced soluble syndecan-1 concentration correlated positively with the duration of retinal detachment and inversely with the age of patients.

Objectives Recent studies have shown that YKL-40 is a new biomarker in patients with coronary artery disease (CAD). YKL-40 is a chitinase-like glycoprotein encoded by the chitinase 3-like 1 gene, CHI3L1, that is localised at a highly conserved area on chromosome 1q32.1. The polymorphisms in the promoter of CHI3L1, −131 C>G (rs4950928), was reported to be associated with the inflammatory-mediated disease asthma and a decreased serum level of YKL-40.We recently showed that plasma YKL-40 levels are significantly increased in patients with CAD. In this study, we intended to investigate whether the SNP −131 C>G (rs4950928), which affect the serum level of YKL-40, is associated with CAD. Methods Results Significant clinical correlates of YKL-40 plasma levels were sex, age, cigarette smoking, hypertension, hyperlipidaemia and diabetes. Compared with a control group, plasma YKL-40 and hsCRP levels were significantly higher in CAD group (36.46±27.42 ng/ml vs 71.79±104.85 ng/ml, p 2 =1, but the LD was disturbed in Chinese. Conclusions Plasma YKL-40 levels were significantly increased in patients with CAD. A promoter polymorphism (−131C>G) in CHI3L1 gene is associated with circulating levels of YKL-40, but not with coronary artery disease in Southern Han Chinese. Future research is needed to confirm the present findings, by replicating this association in independent populations of various ethnic origins, especially in large-scale prospective cohort studies.